AWARD AMOUNT

Up to $100,000 for entire project period

...

HSCI scientists identify role of protein behind rare Norrie disease

AWARD AMOUNT

Up to $50,000 for one year project period

CALL FOR PROPOSALS

2022 HSCI DIABETES PROGRAM PILOT GRANTS

'Targeted cargo delivery to pancreatic islet cells'

AWARD AMOUNT

Up to $100,000 per year per lab for up to two years

POSTED DATE

December 6, 2021

DEADLINE FOR APPLICATION

January 28, 2022

ANTICIPATED AWARD DATE

April 1, 2022

The Harvard Stem Cell Institute (HSCI) Diabetes Program invites applications for pilot grant funding. The purpose of this call for applications is to fund innovative projects that aim to develop new or leverage existing modalities to deliver genetic payloads to pancreatic islet cells for the therapy of type 1 diabetes. Collaborative proposals are welcome, particulary where one of the labs has expertise in diabetes research. The HSCI diabetes Program intends to award up to two grants in response to this call for proposals, contingent upon the number and quality of the proposals received.... Read more about Call for Proposals: 2022 HSCI Diabetes Program Pilot Grants - 'Targeted cargo delivery to pancreatic islet cells'

CALL FOR PROPOSALS

2022 HSCI DIABETES PROGRAM PILOT GRANTS

'Learning from cancer immunology to cure autoimmune diabetes'

AWARD AMOUNT

Up to $100,000 per year per lab for up to two years

POSTED DATE

December 6, 2021

DEADLINE FOR APPLICATION

January 28, 2022

ANTICIPATED AWARD DATE

April 1, 2022

The Harvard Stem Cell Institute (HSCI) Diabetes Program invites applications for pilot grant funding. The purpose of this call for applications is to fund innovative projects rooted in our understanding of tumor-immune interactions to avert the immune attack on pancreatic islet cells that underlies type 1 diabetes. A particular focus of the Diabetes Program lies in developing solutions that will enable the transplantation of stem cell-derived islet cells into patients with autoimmune diabetes. Approaches of interest include – but are not limited to – novel immune interventions to regulate or eliminate autoreactive T lymphocytes, interventions to modify local antigen presentation, and genetic manipulations of stem cell-derived islet cells to protect them against allo- and autoimmunity. Collaborative proposals are welcome, particulary where one of the labs has expertise in diabetes research. The HSCI diabetes Program intends to award up to two grants as a result of this call for proposals.... Read more about Call for Proposals: 2022 HSCI Diabetes Program Pilot Grants - 'Learning from cancer immunology to cure autoimmune diabetes'

2022 HSCI Nervous System Disease Program

Request for Proposals on Vision Repair and Regeneration

AWARD AMOUNT

Trainee Awards will be made in amounts of up to $75,000 total funding per year.

Faculty Awards will be made in amounts of up to $150,000 total funding per year.

Up to $300,000 for entire project period.

Project period not to exceed 2 years

DEADLINE FOR LETTER OF INTENT

** EXTENDED **
Wednesday, February 2, 2022

DEADLINE FOR FULL PROPOSAL

** EXTENDED **
Friday, February 25, 2022

ANTICIPATED AWARD DATE

April 1, 2022

... Read more about 2022 HSCI Nervous System Disease Program Request for Proposals on Vision Repair and Regeneration

Bone metastases are devastating developments of cancers that originate in other organs. In the case of metastatic prostate cancer, bone metastases represent an incurable, painful, and often deadly development, killing more than 30,000 American men every year. Unlike many other tumor types, metastatic prostate cancer responds poorly to immune-based therapies, but a new study published in Cancer Cell and originating in part from Harvard Stem Cell Institute (HSCI) labs, has uncovered a key mechanism for why such therapies fail to work, potentially leading the way to a breakthrough in the treatment of this devastating disease.... Read more about A new study illuminates the therapy resistance of metastatic prostate cancer

Tuberous Sclerosis Complex (TSC) is an incurable genetic disease that causes tumor formation in various organs. In the kidney, the growth of renal angiomyolipomas (AMLs) can lead to loss of renal function and premature death caused by the spontaneous rupture of vascular aneurysms. For the last three decades, our understanding of AML biology has been greatly limited by the lack of appropriate experimental models. However, in a new paper published in Nature Communications, researchers from the lab of Dario Lemos, HSCI Affiliate Faculty, report a landmark bioengineering method for modelling the renal manifestations of this rare disease, laying the groundwork for the testing of new therapies.... Read more about New Bioengineering Approach Replicates Rare Kidney Tumor

Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). In conjunction with immunosuppressive therapy, VX-880 produced robust restoration of islet cell function on Day 90 in the first patient in its Phase 1/2 clinical trial.... Read more about A new therapy for treating Type 1 diabetes

CALL FOR PROPOSALS

2021 HSCI MUSCULOSKELETAL DISEASE PROGRAM PILOT GRANTS

AWARD AMOUNT
Up to $100,000 for entire project period
Project period not to exceed two years
POSTED DATE
Friday, October 8, 2021
DEADLINE FOR APPLICATION
Friday, November 12, 2021
ANTICIPATED AWARD DATE
January 1, 2022
 

The Harvard Stem Cell Institute (HSCI) Musculoskeletal (MSK) Disease Program invites applications for pilot grant funding. The purpose of this program is to provide funding for innovative projects in the field of musculoskeletal stem cell and regenerative biology. HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures for musculoskeletal injuries or disease. However, proposals at all stages of development are welcome, as are proposals that encompass a collaboration between two MSK labs where at least one of the labs is member of the HSCI. The HSCI MSK Program intends to award up to two grants in response to this call for proposals, contingent upon the number and quality of the proposals received, as well as the availability of HSCI MSK Disease Program funds.... Read more about Call for Proposals: 2021 HSCI Musculoskeletal Disease Program Pilot Grants

A group of researchers, led by HSCI Co-Director David Scadden, MD, has shown that bone cells pass packets of genetic material directly to bone progenitors, increasing blood production and stimulating the immune cells necessary to fight infection. ... Read more about A new signaling system for blood regeneration

A Harvard Stem Cell Institute (HSCI) led collaboration developed a new macroencapsulation device (MED) that protects the insulin-producing cells of the pancreas and enhances their survival with improved nutrient supply. ... Read more about Bioartificial device offers potential for treatment of Type 1 diabetes